Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,536 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,903 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00790374 | BN83495 in Prostate Cancer(STX64PC) | completed | Phase 1 | 17 | IpsenINDUSTRY | 1 | Jan 15, 2019 | clinicaltrials |
| NCT02950064 | A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations | unknown | Phase 1 | 95 | Placon TherapeuticsINDUSTRY | 1 | Jan 14, 2019 | clinicaltrials |
| NCT01286987 |
| Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors |
| completed |
| Phase 1 |
| 113 |
| PfizerINDUSTRY |
| 2 |
| Jan 10, 2019 |
| clinicaltrials |
| NCT03450109 | A Study to Assess LY01005 Versus Goserelin Comparator (ZOLADEX®) in Patients With Prostate Cancer | completed | Phase 1 | 19 | Luye Pharma Group Ltd.INDUSTRY | 1 | Jan 7, 2019 | clinicaltrials |
| NCT01262664 | A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity | terminated | Phase 1 | 4 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 4, 2019 | clinicaltrials |
| NCT02655952 | Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients | completed | Phase 1 | 17 | WntResearch ABINDUSTRY | 2 | Dec 28, 2018 | clinicaltrials |
| NCT00924807 | Safety Study of Sorafenib With Androgen Deprivation and Radiotherapy to Treat Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Beth Israel Medical CenterOTHER | 1 | Dec 11, 2018 | clinicaltrials |
| NCT00059631 | Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone | completed | Phase 1 | 42 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 15, 2018 | clinicaltrials |
| NCT00082732 | Behavior-Based Dietary Intervention in Treating Patients With Hormone-Refractory Prostate Cancer | completed | Phase 1 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT00038194 | Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer | completed | Phase 1 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00038246 | Study of Paclitaxel, Estramustine Phosphate and Thalidomide for Patients With Metastatic Androgen-Independent Prostate Carcinoma | completed | Phase 1 / Phase 2 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 31, 2018 | clinicaltrials |
| NCT00379561 | PSA-Activated PSA-PAH1 for Locally Recurrent Prostate Cancer | completed | Phase 1 | 24 | Sophiris Bio CorpINDUSTRY | 1 | Oct 29, 2018 | clinicaltrials |
| NCT02234921 | Pilot Study of DRibble Vaccine for Prostate Cancer Patients(DRibble) | completed | Phase 1 | 3 | UbiVacINDUSTRY | 1 | Oct 11, 2018 | clinicaltrials |
| NCT01144897 | PET Acetate for Castrate-Resistant Prostate Cancer on Chemotherapy | completed | Phase 1 | 5 | Daniel VaenaOTHER | 1 | Oct 2, 2018 | clinicaltrials |
| NCT01497925 | Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer | completed | Phase 1 | 43 | Polaris GroupINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT02058680 | Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients(PSA) | unknown | Phase 1 | 48 | OncBioMune PharmaceuticalsOTHER | 1 | Sep 10, 2018 | clinicaltrials |
| NCT00953576 | Ketoconazole, Hydrocortisone, Dutasteride and Lapatinib (KHAD-L) in Prostate Cancer(KHLAD) | terminated | Phase 1 / Phase 2 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01513733 | The CATCH Prostate Cancer Trial: Cabazitaxel And Tasquinimod in Men With Prostate Cancer(CATCH) | completed | Phase 1 | 25 | Andrew J. Armstrong, MDOTHER | 1 | Sep 4, 2018 | clinicaltrials |
| NCT01303705 | Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer | completed | Phase 1 | 13 | Providence Health & ServicesOTHER | 1 | Aug 29, 2018 | clinicaltrials |
| NCT01496157 | Evaluation of Prostate-specific Membrane Antigen (PSMA)-Based PET Imaging of Primary Prostate Cancer | completed | Phase 1 / Phase 2 | 15 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01815515 | Evaluation of 18F-DCFBC PSMA-based PET Imaging for Detection of Metastatic Prostate Cancer | completed | Phase 1 / Phase 2 | 22 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Aug 20, 2018 | clinicaltrials |
| NCT02297386 | [18F] Dihydro-testosterone Pet and MR Imaging In Patients With Localized Prostate Cancer | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 6, 2018 | clinicaltrials |
| NCT01647789 | A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 4 | Aug 3, 2018 | clinicaltrials |
| NCT03465345 | Study of Metformin Plus Oligomeric Procyanidin Complex for Pharmacologic Manipulation of AGE (Advanced Glycation Endproducts) Levels in Prostate Cancer Patients | withdrawn | Phase 1 | 0 | Medical University of South CarolinaOTHER | 1 | Aug 3, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01983709 | Allogeneic Human Bone Marrow Derived Mesenchymal Stem Cells in Localized Prostate Cancer(MSC) | terminated | Phase 1 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jul 16, 2018 | clinicaltrials |
| NCT01335204 | Ph Ib/IIa Study of Cabazitaxel Plus Bavituximab in Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 4 | Medical University of South CarolinaOTHER | 1 | Jul 13, 2018 | clinicaltrials |
| NCT01296139 | Ferumoxytol Enhanced MRI for the Detection of Lymph Node Involvement in Prostate Cancer | completed | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT00804245 | C-11 Choline PET-CT Scan in Finding Metastases in Patients With Newly Diagnosed High-Risk Prostate Cancer | completed | Phase 1 | 18 | Wake Forest University Health SciencesOTHER | 1 | Jul 3, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00892736 | Veliparib in Treating Patients With Malignant Solid Tumors That Do Not Respond to Previous Therapy | completed | Phase 1 | 98 | National Cancer Institute (NCI)NIH | 1 | Jun 29, 2018 | clinicaltrials |
| NCT00188513 | Intensity Modulated Radiation Therapy - Prostate Cancer | completed | Phase 1 / Phase 2 | 267 | University Health Network, TorontoOTHER | 1 | Jun 12, 2018 | clinicaltrials |
| NCT01385228 | Pazopanib, Docetaxel, Prednisone Prostate | completed | Phase 1 | 36 | Daniel George, MDOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01090765 | A Phase I/II Study of TRC105 in Metastatic Castrate Resistant Prostate Cancer (CRPC) | completed | Phase 1 / Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT02284971 | Pilot Study of SBRT and CDX-1127 in Prostate Cancer(Prostate-04) | terminated | Phase 1 | 2 | James Larner, MDOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03516045 | A Study of 18F-AlF-NOTA-Neurotensin PET/CT for Imaging Prostate Cancer | unknown | Phase 1 / Phase 2 | 65 | Xiangya Hospital of Central South UniversityOTHER | 1 | May 17, 2018 | clinicaltrials |
| NCT03525652 | Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment | unknown | Phase 1 / Phase 2 | 30 | The First Affiliated Hospital of Guangdong Pharmaceutical UniversityOTHER | 1 | May 16, 2018 | clinicaltrials |
| NCT00822510 | Telephone Counseling: Men With Prostate Cancer & Partners | completed | Phase 1 | 79 | University of ArizonaOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT00061347 | Using Fiducial Markers to Aid in Prostate Cancer Radiation Treatment | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Apr 23, 2018 | clinicaltrials |
| NCT02532114 | Niclosamide and Enzalutamide in Treating Patients With Castration-Resistant, Metastatic Prostate Cancer | completed | Phase 1 | 5 | University of WashingtonOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT00096304 | Epirubicin and Docetaxel in Treating Patients With Metastatic Prostate Cancer | terminated | Phase 1 | 36 | Medical University of South CarolinaOTHER | 1 | Apr 10, 2018 | clinicaltrials |
| NCT01934790 | Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone Metastases | completed | Phase 1 / Phase 2 | 45 | BayerINDUSTRY | 7 | Mar 26, 2018 | clinicaltrials |
| NCT01400555 | A Safety Study of Abiraterone Acetate Administered in Combination With Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)(mCRPC) | completed | Phase 1 | 22 | Cougar Biotechnology, Inc.INDUSTRY | 1 | Mar 21, 2018 | clinicaltrials |
| NCT01666314 | Study in Japan and Ex-Japan to Characterize the Pharmacokinetic and Pharmacodynamic Response to Orteronel (TAK-700) in Chemotherapy-Naive Participants With Castration-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 137 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02488070 | 68Ga-PSMA PET/CT or PET/MRI in Evaluating Patients With Recurrent Prostate Cancer | completed | Phase 1 / Phase 2 | 10 | Stanford UniversityOTHER | 1 | Mar 20, 2018 | clinicaltrials |
| NCT02349139 | Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer | terminated | Phase 1 | 27 | Asana BioSciencesINDUSTRY | 1 | Mar 7, 2018 | clinicaltrials |
| NCT02606123 | Safety and Anti-Tumor Study of Oral EPI-506 for Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | ESSA PharmaceuticalsINDUSTRY | 2 | Mar 1, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Jan 15, 2019source: clinicaltrials